Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
Open Access
- 1 September 2011
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy
- Vol. 19 (9), 1737-1746
- https://doi.org/10.1038/mt.2011.113
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSFMolecular Therapy, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard careBritish Journal of Cancer, 2010
- In situ adenovirus vaccination engages T effector cells against cancerVaccine, 2009
- The anticancer immune response: indispensable for therapeutic success?JCI Insight, 2008
- Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytesClinical and Experimental Immunology, 2007
- Immune surveillance of tumorsJCI Insight, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cellsThe Journal of Experimental Medicine, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006